Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Kobayashi Pharmaceutical Co (KBYPF) Stock Price & Analysis

6 Followers

KBYPF Stock Chart & Stats

$39.47$0.00(0.00%)
At close: 4:00 PM EST
$40$50Nov 8Sep 21Mar 22Nov 22Sep 2Jan 16Sep 24
Day’s Range
$39.47 - $40.76
52-Week Range
$30.74 - $41.44
Previous Close
$39.47
Volume
N/A
Average Volume (3M)
0
Market Cap
$3.27B
Enterprise Value
$462.48B
Total Cash (Recent Filing)
$57.33B
Total Debt (Recent Filing)
$723.00M
Price to Earnings (P/E)
318.7
Beta
0.37
Next Earnings
Feb 16, 2027 (Est.)
EPS Estimate
0.27
Next Dividend Ex-Date
Dec 31, 2026
Dividend Yield
1.67%

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Minimal debt and a large, stable equity base provide substantial financial resilience. This reduces dependence on refinancing, preserves flexibility for product investment and marketing, and gives the company greater capacity to withstand earnings volatility over the next several quarters.

Improved 2025 Cash Generation

The 2025 rebound in operating and free cash flow indicates improved cash generation after the prior-year shortfall. If sustained, stronger internal funding can support brand investment, product development and shareholder returns without requiring significant additional borrowing.

Diversified Branded Consumer Model

A portfolio spanning OTC medicines, recurring-use personal-care goods and household consumables diversifies revenue sources. Company-owned brands, repeat purchases and broad retail distribution can support customer retention and durable demand across multiple everyday product categories.

Bears Say

Sharp Profitability Deterioration

The sustained decline in net income and operating profit materially weakens earnings quality despite the stable revenue base. Lower profitability can constrain reinvestment, reduce returns on equity and make the business more sensitive to execution challenges over the medium term.

Limited Revenue Growth

Low or inconsistent revenue growth limits the company’s ability to offset cost pressure and rebuild profitability through operating scale. A largely flat top line also places greater importance on successful product launches, brand investment and margin recovery to improve earnings.

Volatile Cash Conversion

The large year-to-year swings in free cash flow indicate that accounting earnings have not translated consistently into cash. Although 2025 improved, renewed volatility could limit predictable investment capacity and complicate long-term capital allocation decisions.

Kobayashi Pharmaceutical Co News

KBYPF FAQ

What was Kobayashi Pharmaceutical Co’s price range in the past 12 months?
Kobayashi Pharmaceutical Co lowest stock price was $30.74 and its highest was $41.44 in the past 12 months.
What is Kobayashi Pharmaceutical Co’s market cap?
Kobayashi Pharmaceutical Co’s market cap is $3.27B.
When is Kobayashi Pharmaceutical Co’s upcoming earnings report date?
Kobayashi Pharmaceutical Co’s next earnings report is estimated for Feb 16, 2027 (not yet confirmed), which is in 97 days.
How were Kobayashi Pharmaceutical Co’s earnings last quarter?
Kobayashi Pharmaceutical Co released its earnings results on Nov 10, 2026. The company reported $0.559 earnings per share for the quarter, beating the consensus estimate of $0.406 by $0.152.
Is Kobayashi Pharmaceutical Co overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Kobayashi Pharmaceutical Co pay dividends?
Kobayashi Pharmaceutical Co pays a semiannual dividend of $0.396 which represents an annual dividend yield of 1.67%. See more information on Kobayashi Pharmaceutical Co dividends here
What is Kobayashi Pharmaceutical Co’s EPS estimate?
Kobayashi Pharmaceutical Co’s EPS estimate is 0.27.
How many shares outstanding does Kobayashi Pharmaceutical Co have?
Kobayashi Pharmaceutical Co has 78,050,000 shares outstanding.
What happened to Kobayashi Pharmaceutical Co’s price movement after its last earnings report?
Kobayashi Pharmaceutical Co reported an EPS of $0.559 in its last earnings report, beating expectations of $0.406. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kobayashi Pharmaceutical Co?
Currently, no hedge funds are holding shares in KBYPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology